Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: A randomized controlled trial

JAMA

Volumn 283, Issue 8, 2000, Pages 1016-1024

  Treanor, John J ^a   Hayden, Frederick G ^b   Vrooman, Peter S ^b   Barbarash, Rick ^b   Bettis, Robert ^b   Riff, Dennis ^b   Singh, Sudeep ^b   Kinnersley, Nelson ^b   Ward, Penelope ^b   Mills, Roger G ^b  

^a UNIVERSITY OF ROCHESTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; PLACEBO; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SINUSITIS; VOMITING;

EID: 17744412173     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.283.8.1016     Document Type: Article

References (38)

1. Sullivan KM, Monto AS, Longini IM. Estimates of the US health impact of influenza. Am J Public Health. 1993;83:1712-1716.
2. Brown LE, Hampson AW, Webster RG, eds. Options for the Control of Influenza III. New York, NY: Elsevier Science BV; 1996:17-25.
3. Kavet J. A perspective on the significance of pandemic influenza. Am J Public Health. 1977;67:1063-1070.
4. Schoenbaum SC. Economic impact of influenza. Am J Med. 1987;82(suppl 6A):26-30.
5. Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med. 1989;321:1696-1702.
6. Hayden FG, Gwaltney JM Jr, van de Castle RL, et al. Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults. Antimicrob Agents Chemother. 1981;19:226-233.
7. Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N Engl J Med. 1997;337:874-880.
8. MIST Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet. 1998;352:1877-1881.
9. Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis. 1999;180:254-261.
10. Calfee DP, Peng AW, Cass LMR, et al. Protective efficacy of intravenous zanamivir in experimental human influenza. 38th International Conference on Antimicrobial Agents and Chemotherapy; September 24-27, 1998; San Diego, Calif. Abstract A332.
11. Kim CU, Lew W, Williams MA, et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site. J Am Chem Soc. 1997;119:681-690.
12. Mendel DB, Tai CY, Escarpe PA, et al. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother. 1998;42:640-646.
13. Wood ND, Aitken M, Sharp S, Evison H. Tolerability and pharmacokinetics of the neuraminidase inhibitor Ro 64-0802 (GS4071) following oral administration of the prodrug Ro 64-0796 (GS4104) to healthy male volunteers. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 28-October 1, 1997; Toronto, Ontario. Abstract A123.
14. Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza. JAMA. 1999;282:1240-1246.
15. Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med. 1999;341:1336-1346.
16. Protecting Human Research Subjects. Washington, DC: US Government Printing Office; 1993. National Institutes of Health Publication 93-3470.
17. Mahy BW, Kangro HO, eds. Virology Methods Manual. New York, NY: Harcourt Brace; 1996:25-46.
18. Lenette EH, Schmidt NJ, eds. Diagnostic Procedures for Viral, Rickettsial, and Chlamydial Infections. 5th ed. Washington, DC: American Public Health Association; 1979:603-605.
19. Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics. 1982;38: 29-41.
20. Aoki F, Osterhaus A, Rimmelzwaan G, Kinnersley N, Ward P. Oral GS4104 successfully reduces duration and severity of naturally acquired influenza. 38th International Conference on Antimicrobial Agents and Chemotherapy; September 24-27, 1998; San Diego, Calif: Abstract LB-5.
21. Barker WH, Mullooly JP. Impact of epidemic type A influenza in a defined adult population. Am J Epidemiol. 1980;112:798-813.
22. Barker WH, Mullooly JP. Pneumonia and influenza deaths during epidemics. Arch Intern Med. 1982; 142:85-89.
23. Nicholson KG, Webster RG, Hay AJ, eds. Textbook of Influenza. Oxford, England: Blackwell; 1998: 219-266.
24. Kaiser L, Hayden FG, Hammond JM, Keene O. Efficacy of inhaled zanamivir in reducing complications and antibiotic use in influenza. 39th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26-29, 1999; San Francisco, Calif. Abstract A1903.
25. Smith AP, Thomas M, Brockman P, Kent J, Nicholson KG. Effect of influenza B virus infection on human performance. BMJ. 1993;306:760-761.
26. Keech M, Scott AJ, Ryan PJ. The impact of influenza and influenza-like illness on productivity and healthcare resource utilization in a working population. Occup Med. 1998;48:85-90.
27. Galbraith AW, Oxford JS, Schild GC, Watson GI. Study of 1-adamantanamine hydrochloride used propyhlactically during the Hong Kong influenza epidemic in the family environment. Bull World Health Organ. 1969;41:677-682.
28. Togo Y, Hornick RB, Felitti VJ, et al. Evaluation of the therapeutic efficacy of amantadine in patients with naturally occurring A2 influenza. JAMA. 1970;211:1149-1156.
29. Galbraith AW, Oxford JS, Schild GC, Potter CW, Watson GI. Therapeutic effect of 1-adamantanamine hydrochloride in naturally occurring influenza A2-Hong Kong infection. Lancet. 1971;1:113-115.
30. Van Voris LP, Betts RF, Hayden FG, Christmas WA, Douglas RG Jr. Successful treatment of naturally occurring influenza A/USSR/77 H1N1. JAMA. 1981; 245:1128-1131.
31. Younkin SW, Betts RF, Roth FK, Douglas RG Jr. Reduction in fever and symptoms in young adults with influenza A/Brazil/78 H1N1 infection after treatment with aspirin or amantadine. Antimicrob Agents Chemother. 1983;23:577-582.
32. Hayden FG, Monto AS. Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults. Antimicrob Agents Chemother. 1986;29:339-341.
33. Hayden FG, Sperber SJ, Belshe RB, Clover RD, Hay AJ, Pyke S. Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrob Agents Chemother. 1991;35:1741-1747.
34. Wiltshire HR, Muir J, Lambkin R, Davies S. Distribution of the influenza neuraminidase inhibitor GS4071 following oral administration of its prodrug GS4104 in ferrets. European Society for Clinical Virology; August 30-September 2,1998; Hamburg, Germany. Abstract A218.
35. Monto AS, Arden NH. Implications of viral resistance to amantadine in control of influenza A. Clin Infect Dis. 1992;15:362-367.
36. Degelau J, Somani SK, Cooper SL, Guay DR, Crossley KB. Amantadine-resistant influenza A in a nursing facility. Arch Intern Med. 1992;152:390-392.
37. Gubareva LV, Robinson MJ, Bethell RC, Webster RG. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Aeu5Ac2en. J Virol. 1997; 71:3385-3390.
38. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis. 1998;178:1257-1262.